Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674332 | SCV000799654 | uncertain significance | Pyruvate dehydrogenase E3 deficiency | 2018-04-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000674332 | SCV002283051 | likely pathogenic | Pyruvate dehydrogenase E3 deficiency | 2020-11-13 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Arg495 amino acid residue in DLD. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 21930696, 8968745). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This variant has not been reported in the literature in individuals with DLD-related conditions. ClinVar contains an entry for this variant (Variation ID: 558106). This variant is not present in population databases (ExAC no frequency). This sequence change results in a frameshift in the DLD gene (p.Pro488Argfs*60). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 22 amino acid(s) of the DLD protein and extend the protein by 37 additional amino acid residues. |